A new player in the treatment of HER2-positive tumours

Affiliations

¹ Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo 10060, Italy.
² Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo 10060, Italy. Electronic address: filippo.montemurro@ircc.it.

Comment

Gaia Giannone et al. Lancet Oncol. 2019 Jun.

. 2019 Jun;20(6):748-750.

doi: 10.1016/S1470-2045(19)30168-8. Epub 2019 Apr 29.

¹ Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo 10060, Italy.
² Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo 10060, Italy. Electronic address: filippo.montemurro@ircc.it.

No abstract available

Comment on

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Tamura K, et al. Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047803 Clinical Trial.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Shitara K, et al. Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047804 Clinical Trial.